Loading...
Kazia Therapeutics Limited
KZA.AX•ASX
Healthcare
Biotechnology
A$0.08
A$0.007(9.59%)
Kazia Therapeutics Limited (KZA.AX) Financial Performance & Income Statement Overview
Review Kazia Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
415755.86%
↑ 415755.86%
Operating Income Growth
100.00%
↑ 100.00%
Net Income Growth
-30.85%
↓ 30.85%
Operating Cash Flow Growth
36.78%
↑ 36.78%
Operating Margin
-4346661.08%
↓ 4346661.08%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-3687419.82%
↓ 3687419.82%
ROE
-133.37%
↓ 133.37%
ROIC
-117.56%
↓ 117.56%
Kazia Therapeutics Limited (KZA.AX) Income Statement & Financial Overview
Review Kazia Therapeutics Limited's (KZA.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2024 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $5.00 | $278.00 | $278.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $5.00 | $278.00 | $278.00 | $0.00 |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $0.00 |
| R&D Expenses | $4.33M | $3.10M | $3.10M | $4.68M |
| SG&A Expenses | $4.56M | $2.15M | $2.15M | $2.14M |
| Operating Expenses | $8.88M | $3.52M | $3.52M | $6.86M |
| Total Costs & Expenses | $8.88M | $3.52M | $3.52M | $6.86M |
| Interest Income | $6453.00 | $11209.00 | $11209.00 | $70.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $934705.00 | $467359.00 | $467359.00 | $467371.00 |
| EBITDA | -$7.95M | -$4.79M | -$4.79M | -$6.35M |
| EBITDA Ratio | -$1.59M | -$17221.81 | -$17221.81 | $0.00 |
| Operating Income | -$8.88M | -$5.26M | -$5.26M | -$6.82M |
| Operating Income Ratio | -$1.78M | -$18902.95 | -$18902.95 | $0.00 |
| Other Income/Expenses (Net) | -$75656.00 | $1.75M | $1.75M | -$42544.00 |
| Income Before Tax | -$8.96M | -$3.51M | -$3.51M | -$6.86M |
| Income Before Tax Ratio | -$1.79M | -$12616.36 | -$12616.36 | $0.00 |
| Income Tax Expense | $135546.00 | $67773.00 | $67773.00 | $67773.00 |
| Net Income | -$8.82M | -$3.44M | -$3.44M | -$6.79M |
| Net Income Ratio | -$1.76M | -$12372.58 | -$12372.58 | $0.00 |
| EPS | -$3.68 | -$0.02 | -$0.02 | -$0.05 |
| Diluted EPS | -$3.68 | -$0.02 | -$0.02 | -$0.05 |
| Weighted Avg Shares Outstanding | $2.40M | $215.70M | $215.70M | $145.66M |
| Weighted Avg Shares Outstanding (Diluted) | $2.40M | $222.91M | $222.91M | $145.66M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan